Science and tech leaders from the UK and Switzerland have today (December 9) agreed to update the landmark science and research agreement between the two countries, to focus work on some of today’s most pressing challenges, from boosting public health to making the shift to green energy.
The £16 million ($20.4 million) joint funding includes backing to support UK-Swiss clinical trials that could help unlock new treatments and diagnoses for a range of diseases, according to a statement from the UK’S Department for Science, Innovation and Technology.
The communication noted that the UK and Switzerland are natural partners when it comes to science and innovation. Together, the two countries are home to 10 of Europe’s top 20 research universities. To support even closer ties between both countries’ best and brightest, today Innovate UK and the Swiss innovation authority Innosuisse have awarded around £8 million in joint funding to 11 UK-Swiss research projects.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze